• Vaccine Name: DECAVAC
• Target Pathogen: Corynebacterium diphtheriae
• Target Disease: Diphtheria
• Product Name: Tetanus and Diphtheria Toxoids Adsorbed For Adult Use
• Tradename: DECAVAC
• Manufacturer: Sanofi Pasteur, Inc
• Vaccine Ontology ID: VO_0000030
• CDC CVX code: 113
• Type: Toxoid vaccine
• Status: Licensed
• Location Licensed: USA (License #1725)
• Host Species for Licensed Use: Human
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001240
  • Description: It is for intramuscular injection, and is a sterile suspension of alum (aluminum potassium sulfate)-precipitated toxoids in an isotonic sodium chloride solution (Decavac).
• Preparation: The cultures are grown in a modified Mueller and Miller medium. Diphtheria toxins produced during the growth of the cultures are detoxified with formaldehyde. The detoxified materials are then separately purified by serial ammonium sulfate fractionation and diafiltration, and adsorbed onto alum. (FDA: Decavac).
• Immunization Route: Intramuscular injection (i.m.)
• Storage: Store at 2° to 8°C (35° to 46°F). Do not freeze. Do not use vaccine after expiration date.
• Approved Age for Licensed Use: DECAVAC vaccine is indicated for active immunization for the prevention of tetanus and diphtheria. DECAVAC vaccine is approved for use in persons 7 years of age and older (FDA: Decavac).
• Contraindication: Do not use after anaphylaxis or other serious allergic reaction following a previous dose of this vaccine, any other tetanus or diphtheria toxoid containing vaccine, or any component of this vaccine
• Description: It is for intramuscular injection, and is a sterile suspension of alum (aluminum potassium sulfate)-precipitated toxoids in an isotonic sodium chloride solution (FDA: Decavac).

Human Response

• Vaccination Protocol: A clinical study involving 58 individuals 6-58 years of age (FDA: Decavac).
• Side Effects: Side effects include: erythema, tenderness and induration at the injection site and 2% systemic reactions consisting of headache, malaise and temperature elevations. Boosters can accentuate side effects(FDA: Decavac)
• Efficacy: The results that indicated protective levels of antibody were achieved in greater than 90% of the study population after primary immunization with both components. Booster effects were achieved in 100% of the individuals with pre-existing antibody responses (FDA: Decavac).